Aromatase is the enzyme that catalyzes the conversion of androgens to estrogens. Initial
studies of its enzymatic activity and function took place in an environment focused on …

Background Endocrine therapy removes the influence of oestrogen on breast cancer cells
and so hormonal treatments such as tamoxifen, megestrol acetate and …

PURPOSE: The efficacy and tolerability of anastrozole (Arimidex; AstraZeneca, Wilmington,
DE, and Macclesfield, United Kingdom) and tamoxifen were compared as first-line therapy …

Background: Aromatase inhibitors and inactivators have been extensively tested in patients
with advanced breast cancer, but it is unclear whether they offer any survival benefits …

Tamoxifen has been used in the management of breast cancer for over 30 years. Since its
introduction for the treatment of advanced breast cancer, its indications have increased to …

Metastatic breast cancer is incurable but often responsive to treatment. There is little
evidence-based consenus on when to use which treatments, in what combination and for …

The aim of this study was to compare the efficacy and tolerability of the new aromatase
inhibitor 'ARIMIDEX'(anastrozole) with megestrol acetate in the treatment of advanced breast …

Aromatase is a member of the cytochrome P450 superfamily that catalyzes the conversion of
androgens (C 19), namely testosterone and androstenedione, into oestrogens (C 18) …

The successful management of breast cancer remains a major challenge to surgeons and
oncologists in the 21st century. Although the incidence of breast cancer varies throughout …

BACKGROUND Many lines of evidence point to sex hormones as the key factors in breast
carcinogenesis. Classic risk factors include age at menarche, first child birth, and …